4 results about "GSTP1" patented technology

Disclosed are pathogenic mechanisms in pulmonary hypertension and molecular inhibitors of the same. Particularly, GSTP1 (glutathione S-transferase P1) have been demonstrated as having a role in regulating the endothelial ISCU function in pulmonary hypertension. Accordingly, methods for treating pulmonary hypertension in a subject in need thereof comprising administering a therapeutically effective amount of a pharmaceutical composition that inhibits glutathione S-transferase P (GSTP1) and / or increasing ISCU expression are disclosed. The GSTP1 inhibitor can comprise a piperlongumine analog, such as BRD-K34222889, or a derivative thereof.

The invention discloses application of a traditional Chinese medicine composition in preparation of a medicine for reversing pancreatic cancer radiotherapy resistance by destroying redox balance and activating a ferroptosis procedure, and belongs to the technical field of medicine. Based on a new mechanism of pancreatic cancer radiotherapy resistance, i.e., tumor cells obtain resistance by up-regulating glutathione S-transferase P1 (GSTP1) to inhibit 5-lipoxygenase (ALOX5)-mediated ferroptosis, the invention provides a new application of a classic prescription dark plum pill or pharmaceutically acceptable extracts, effective parts or effective components thereof. According to the traditional Chinese medicine composition, by targeting a GSTP1 / ALOX5 axis, redox balance reconstructed in radiotherapy resistant cells is destroyed, lipid peroxidation and ferroptosis are reactivated, and therefore the sensitivity of tumor cells to radiotherapy is recovered. The radiotherapy sensitization effect and the mechanism of the dark plum pills are confirmed through systematic network pharmacology, bioinformatics analysis and in-vivo and in-vitro experiments, a brand new target spot and a treatment strategy are provided for overcoming pancreatic cancer radiotherapy resistance, and a scientific foundation is laid for modern development and clinical application of the dark plum pills.

The invention provides a method for rapidly and sensitively detecting GSTP1 (Glutathione S Transferase Protein 1) hypermethylated promoter DNA (Deoxyribose Nucleic Acid) of prostatic cancer in urine. Based on the liquid gate graphene transistor sensor, a bridge-shaped tetrahedral DNA probe is modified to the surface of a gold gate through a gold-sulfur bond, and a hypermethylated GSTP1 promoter converted by hydrosulphite can be selectively captured. Wherein DNA is treated by hydrosulfite, so that unmethylated cytosine (C) can be converted into uracil (U), and methylated cytosine (5-mC) is kept unchanged. According to the bridge-shaped tetrahedron DNA, due to the influence of electrostatic repulsion and space structure between two tetrahedrons, the transverse distance between curled ssDNA is easily controlled to improve the hybridization efficiency and reduce Debye shielding, the detection limit can be as low as 10-18 M, the wide linear detection range of 10 <-18 >-10 <-8 > M can be achieved, and the detection efficiency is greatly improved. The kit has a good detection effect in complex artificial urine and clinical practical sample detection, can effectively distinguish clinical urine samples of prostatic cancer patients and control groups, and has clinical application value.

The present application relates to the field of biotechnology, and application of a kuding tea and its extract and a product for preventing or treating hypertension. The product has the following effects: reducing the abundance of staphylococcus aureus (SA) in the intestinal tract or / and regulating the composition of the intestinal flora; reducing the level of at least one exotoxin secreted by SA in the body; up-regulating the expression of at least one of glutathione S-transferase and glutathione S-transferase P1 in the hypothalamic paraventricular nucleus. The present application also provides application of GSTM2 / GSTP1 as a target point in a product for preventing or treating hypertension. The present application is applied to a product for up-regulating the antioxidant defense (GSTM2 / GSTP1) of the hypothalamic paraventricular nucleus (PVN) through intestinal SA-exotoxin, and is further applied to prevention and treatment of hypertension. The present application provides a new target point for intervention in reducing blood pressure, and thus prepares a new product such as a drug for preventing and treating hypertension.